BioSpace News Archive

Vivera Pharmaceuticals is excited to announce a distribution partnership with EcoGroup USA for Vivera’s BioZone, an advanced access control device intended for sanitization in high occupancy settings. BioZone is designed to combine facial recognition, integrated biometrics, and a hospital grade FDA and EPA approved organi

Bioventus, a leader in Solutions For Innovative Healing, received authorization to proceed under its investigational new drug (IND) application from the US Food and Drug Administration (FDA), allowing it to proceed to clinical trials of PTP-001

As previously announced, during April 2020, Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga”) and Aegea Biotechnologies, Inc. (“Aegea”) have entered into a collaboration agreement to develop COVID-19 (novel coronavirus) assays.

OpSens Inc. has been recognized in Deloitte’s 2020 Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies in North America.

Evommune, Inc., an innovation engine in chronic inflammation, announced the successful completion of a $12.5 million seed financing by Pivotal bioVenture Partners.

The Allen Institute announced six new Next Generation Leaders, members of a unique neuroscience advisory panel made up of early-career researchers.

Geisinger has been selected as one of seven finalists in the Centers for Medicare & Medicaid (CMS) Artificial Intelligence Health Outcomes Challenge.

Young people around the world commonly experience anxiety and depression, but it can be hard to identify how each person can best manage their own mental health.

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat multi-drug resistant bacterial infectious diseases, today announced clearance by the U.S. Food and Drug Administration (FDA) of the company’s Expanded Access IND for PhageBank™ treatment for pneumonia or bacteremia/septicemia due to Acinetobacter baumannii, Pseudomonas aeruginosa or Staphylococcus aureus in COVID-19 patients.

Rare Disease Advisory Councils enable the rare community to have a say in how their state’s programs and policies can support patients and caregivers